Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An update from Nanobiotix ( (NBTX) ) is now available.
Nanobiotix has announced the details of its voting rights and share capital as of December 31, 2024, with 47,426,851 shares outstanding and a total of 49,204,910 theoretical voting rights. This update is crucial for stakeholders to understand the company’s governance structure and potential implications for shareholder decision-making, reflecting the company’s transparency in public disclosures.
More about Nanobiotix
Nanobiotix is a late-stage clinical biotechnology company based in Paris, France, specializing in disruptive, physics-based therapeutic approaches to improve treatment outcomes. Established in 2003, it operates across the oncology, bioavailability, and central nervous system disorder sectors, holding over 25 patent families. The company is listed on Euronext Paris and Nasdaq, with subsidiaries, including one in Cambridge, Massachusetts.
YTD Price Performance: -1.38%
Average Trading Volume: 30,326
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $141.4M
Find detailed analytics on NBTX stock on TipRanks’ Stock Analysis page.
